Featured Post
Clinical Update Based on Data Presented at the EASL International Liver...
June 28, 2021 / 0 Minute Read
Posts for industry: Imdusiran (AB-729)
Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects...
June 23, 2021 / 0 Minute Read
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729...
June 23, 2021 / 0 Minute Read
A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions...
June 23, 2021 / 0 Minute Read
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis...
June 23, 2021 / 0 Minute Read
An RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical...
May 5, 2021 / 0 Minute Read
AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and...
February 4, 2021 / 0 Minute Read
AB-729 Clinical Update
November 16, 2020 / 0 Minute Read
Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic...
November 15, 2020 / 0 Minute Read
AB-729 Clinical Update
May 18, 2020 / 0 Minute Read
AB-729-001
A Phase 1a/1b clinical trial evaluating the safety, tolerability, and PK/PD of single and multiple-ascending dose of imdusiran in healthy subjects and patients with cHBV infection.
Preliminary data suggest that imdusiran is generally safe and well tolerated through 48 weeks of dosing and long-term suppression of HBsAg with imdusiran results in increased HBV-specific immune response. Patients who have discontinued all therapy are continuing to be followed.